SLS009 was well-tolerated with no new safety signals observed to date as the regimen remains safe in additional patients enrolled to date.

Cantor Fitzgerald has recently initiated Sellas Life Sciences Group Inc (SLS) stock to Overweight rating, as announced on July 21, 2021, according to Finviz. Earlier, on November 1, 2018, Oppenheimer ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on SELLAS Life Sciences Group (SLS – Research Report), retaining the price target ...

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...

Cantor Fitzgerald has recently initiated Sellas Life Sciences Group Inc (SLS) stock to Overweight rating, as announced on July 21, 2021, according to Finviz. Earlier, on November 1, 2018, Oppenheimer ...

(RTTNews) - Sellas Life Sciences Group, Inc. (SLS), Wednesday announced positive data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective CDK9 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...

For more information on the study, visit clinicaltrial.gov identifier NCT04588922. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the ...

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...